Selective Serotonin Reuptake Inhibitors Response and the Impact of CYP2C19 Metabolizer Status. Precision Medicine Communications, [S. l.], v. 2, n. 1, p. 05–07, 2022. DOI: 10.55627/pmc.002.01.0097. Disponível em: https://rootspress.org/journals/index.php/PMC/article/view/97. Acesso em: 8 may. 2026.